Table 3

Details of systemic chemotherapy
Patients who received chemotherapy
(n = 38 patients undergoing 56 resections)
Timing of treatment
Chemotherapy plus targeted agent n = 11 resections (in 9 patients)
 Neoadjuvant plus adjuvant 7 (64%)
 Neoadjuvant alone 4 (36%)
 Adjuvant alone 0
Chemotherapy alone n = 38 resections (in 29 patients)
 Neoadjuvant plus adjuvant 15 (39%)
 Neoadjuvant alone 13 (34%)
 Adjuvant alone 10 (26%)
None* n = 7 resections
Type of systemic treatment
Targeted agents n = 11 resections (in 9 patients)
 Bevacizumab 8
 Cetuximab 2
 Sunitinib 1
Chemotherapy alone n = 38 resections (in 29 patients)
 Oxaliplatin 22
 Irinotecan 6
 Mitomycin 5
 5FU/Cape alone 5
Number of cycles Median (range)
Pre-operative 4 (2–12)
 Targeted agents 6 (4–12)
 Chemo alone 4 (2–8)
Post-operative 5 (2–12)
 Targeted agents 6 (4–12)
 Chemo alone 4 (2–12)
Chemotherapy-related complications
Pre-operative 9 events (8 patients)
 G3/4 neutropenia 2
 G3/4 Thrombocytopenia 1
 ≥G2 neuropathy 2
 G3/4 diarrhoea 1
 G3/4 Chest pain 2
 G3 VTE (DVT) 1
Post-operative 19 events (14 patients)
 G3/4 neutropenia 4
 G3/4 Thrombocytopenia 1
 ≥G2 neuropathy 3
 G3/4 diarrhoea 3
 G3 fatigue 2
 G3 infection 1
 G3 GI bleed 1
 G3 PPE 1
 G3 stomatitis 1
 G3 nausea 1
 VTE (pulmonary embolism) 1

Numbers in table refer to number of resections unless otherwise specified.

*7 resections occurred where patients received no chemotherapy, but had received for a prior or subsequent resection.

VTE venous thromboembolism, DVT deep vein thrombosis.

Hawkes et al.

Hawkes et al. BMC Cancer 2012 12:326   doi:10.1186/1471-2407-12-326

Open Data